Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes
Recruiting · NCT07131670 · Observational (researchers observe without assigning treatment) · Lead sponsor: Qian Chu
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This prospective observational study aims to evaluate symptom burden and symptom clusters among lung cancer patients undergoing definitive concurrent chemoradiotherapy (CRT), based on electronic patient-reported outcomes (ePROs). Patients will complete the validated MDASI-LC and EQ-5D instruments weekly from baseline through the end of CRT and for 12 weeks post-treatment. The study will characterize the longitudinal trajectories of symptom severity and interference, identify distinct symptom clusters and their temporal patterns, and explore patient-level predictors of symptom burden. The findings may support the development of personalized symptom management strategies and improve quality of life during and after CRT.
Who can take part
Inclusion criteria
- Pathologically confirmed unresectable stage III NSCLC or limited-stage SCLC
- Age ≥ 18 years
- Receiving definitive chemoradiotherapy
- Able and willing to complete electronic questionnaires
- Provided written informed consent
Exclusion criteria
- Severe comorbidities (heart, liver, kidney)
- Psychiatric illness or cognitive impairment
- Prior chest or mediastinal radiotherapy
Where it is running
1 location listed.
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology - Wuhan, Hubei, China